<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04966624</url>
  </required_header>
  <id_info>
    <org_study_id>BOUHEMAD Abagri 2021</org_study_id>
    <nct_id>NCT04966624</nct_id>
  </id_info>
  <brief_title>Ventilatory Strategy Based on Ultrasound Lung Morphology in Patients With Focal ARDS</brief_title>
  <acronym>LUVS</acronym>
  <official_title>Ventilatory Strategy Based on Ultrasound Lung Morphology in Patients With Focal ARDS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ARDS is characterized by a diffuse, bilateral, extensive alveolar-interstitial infiltrate&#xD;
      related to damage to the alveolar membrane.&#xD;
&#xD;
      Studies of lung morphology assessed by CT scan have shown 2 types of ARDS. When the loss of&#xD;
      ventilation is posterior and caudal, and the pulmonary parenchyma is otherwise &quot;healthy&quot;,&#xD;
      ARDS is said to be focal. When the loss of ventilation is diffuse, associated with excess&#xD;
      tissue affecting the entire lung parenchyma, ARDS is said to be non-focal or diffuse.&#xD;
&#xD;
      Only one recent multicenter study has evaluated whether individualized PEEP adjustment&#xD;
      according to lung morphology (focal vs. non-focal) could improve ARDS survival outcomes&#xD;
      compared with standard of care. Results for the primary endpoint, 90-day mortality, were&#xD;
      negative. But lung morphology was misclassified on CT occurred 85 (21%) of 400 patients. In&#xD;
      addition, per-protocol analysis in which misclassified patients were excluded showed that&#xD;
      mortality was significantly lower in the personalized ventilation group than in the control&#xD;
      group.&#xD;
&#xD;
      Lung ultrasound may be the ideal bedside imaging technique. The loss of pulmonary aeration&#xD;
      and its variations induced by therapeutic maneuvers can be quantified by lung ultrasound.&#xD;
      Lung ultrasound is a non-invasive, non-ionizing radiation method that can be easily used at&#xD;
      the bedside.&#xD;
&#xD;
      APRV ventilation coupled with spontaneous breathing activity prevents atelectasis formation,&#xD;
      recruits less ventilated areas, prevents mechanical ventilation-induced lung injury and&#xD;
      improves lung compliance.&#xD;
&#xD;
      The hypothesis is that a &quot;LUVS&quot; ventilatory strategy composed of a bundle of measures all&#xD;
      aiming at reopening the atelectatic pulmonary zones in focal ARDS (synergistic effect of&#xD;
      spontaneous ventilation in APRV mode, early prone sessions, and adjustment of PEEP according&#xD;
      to the patient's BMI), could decrease the number of days under mechanical ventilation,&#xD;
      compared to protective ventilation with low tidal volume according to the current&#xD;
      international recommendations&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">October 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of days without invasive ventilation</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Focal Acute Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>interventional</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>LUVS&quot; ventilatory strategy composed of a bundle of measures</intervention_name>
    <description>Ventilation in APRV mode early prone sessions, adjustment of positive expiratory pressure according to the patient's BMI and no curarization</description>
    <arm_group_label>interventional</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ventilatory management according to international recommendations (Société de Réanimation de la Langue Française)</intervention_name>
    <description>Ventilatory management according to international recommendations (Société de Réanimation de la Langue Française)</description>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  person who has given oral consent or has been included in an emergency&#xD;
&#xD;
          -  Older than 18 years&#xD;
&#xD;
          -  On mechanical ventilation for less than 24 hours&#xD;
&#xD;
          -  Diagnosis of ARDS for less than 24 hours. ARDS according to the Berlin classification:&#xD;
             i.e. arterial oxygen pressure to inspired oxygen fraction ratio less than or equal to&#xD;
             300, with a PEEP greater than or equal to 5, presence of bilateral radiological&#xD;
             infiltrates not fully explained by heart failure or volume overload&#xD;
&#xD;
          -  Focal ARDS determined on pulmonary ultrasound&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  person who is not a beneficiary of national health insurance&#xD;
&#xD;
          -  person who is subject to a legal measure of protection (curatorship, guardianship)&#xD;
&#xD;
          -  pregnant or breastfeeding women&#xD;
&#xD;
          -  minor&#xD;
&#xD;
          -  Patient having benefited from an invasive mechanical ventilation of more than one week&#xD;
             in the previous month;&#xD;
&#xD;
          -  ARDS in the previous month;&#xD;
&#xD;
          -  Chronic respiratory failure under NIV or long term oxygen;&#xD;
&#xD;
          -  Severe acute asthma;&#xD;
&#xD;
          -  Lobectomy;&#xD;
&#xD;
          -  Pneumothorax;&#xD;
&#xD;
          -  Pneumomediastinum;&#xD;
&#xD;
          -  Pulmonary fibrosis;&#xD;
&#xD;
          -  Morbid obesity with a BMI above 40 ;&#xD;
&#xD;
          -  Cancer with metastasis;&#xD;
&#xD;
          -  Bone marrow transplantation;&#xD;
&#xD;
          -  Chemotherapy-induced neutropenia;&#xD;
&#xD;
          -  Cirrhosis with a Child-Pugh score of C;&#xD;
&#xD;
          -  Suspected or confirmed intracranial hypertension;&#xD;
&#xD;
          -  Concurrent participation in another ARDS study;&#xD;
&#xD;
          -  Extensive burns on the torso.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>BOUHEMAD Belaid</last_name>
    <phone>03 80 29 30 79</phone>
    <email>belaid.bouhemad@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu Dijon Bourgogne</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>ABAGRI Sohel</last_name>
      <email>sohel.abagri@chu-dijon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 8, 2021</study_first_submitted>
  <study_first_submitted_qc>July 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2021</study_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

